Equities

Cutia Therapeutics

Cutia Therapeutics

Actions
  • Price (HKD)14.60
  • Today's Change0.540 / 3.84%
  • Shares traded482.00k
  • 1 Year change-32.25%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,2731,0771,378
Total Receivables, Net774.120.50
Total Inventory45201.80
Prepaid expenses213821
Other current assets, total0.736.800.46
Total current assets1,4161,1451,402
Property, plant & equipment, net23124063
Goodwill, net------
Intangibles, net7.810.600.22
Long term investments------
Note receivable - long term425426
Other long term assets7.673.542.30
Total assets1,7071,4471,495
LIABILITIES
Accounts payable2000.34
Accrued expenses493713
Notes payable/short-term debt8900
Current portion long-term debt/capital leases518.833.72
Other current liabilities, total45312.39
Total current liabilities2557719
Total long term debt1032,6152,266
Total debt2442,6242,269
Deferred income tax------
Minority interest------
Other liabilities, total00.400.40
Total liabilities3582,6932,285
SHAREHOLDERS EQUITY
Common stock0.040.010.01
Additional paid-in capital4,686259259
Retained earnings (accumulated deficit)(3337)(1505)(1050)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,349(1246)(791)
Total liabilities & shareholders' equity1,7071,4471,495
Total common shares outstanding304304304
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.